Report on the risk assessment of 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

Lisbon March 2022

Series type: Risk assessments

Summary

This publication presents the data and findings of the risk assessment on 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC), carried out by the extended Scientific Committee of the EMCDDA on 18 November 2021. On the basis of the Risk Assessment Report, on 18 March 2022, the Commission decided that 3-MMC should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA. 
 

Download as PDF

Table of contents

  • Acknowledgements
  • Foreword
  • EMCDDA Initial Report on 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC)
  • Risk assessment report on a new psychoactive substance: 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC)
  • Annex 1: Technical report on the new psychoactive substance 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC)
  • Annex 2: Participants of the risk assessment meeting, 18 November 2021
Cover of the 3-MMC risk assessment
Pub. Author: 
EMCDDA
Issue: 
34
Pages: 
131
Price: 
Free
ISBN: 
978-92-9497-706-9
ISSN: 
1725-4493
Pub. DOI: 
10.2810/71344
Catalog Number: 
TD-AK-22-004-EN-N

Related links: 

Main subject

NPS

Keywords

3-MMC
early warning system
NPS
synthetic cathinones
synthetic drugs
toxicology

Target audience

policymaker
researcher

Publications

Loading